Evolving trends in the management of pelvic inflammatory disease (PID) during SARS-CoV-2 pandemic: A multicenter retrospective cohort study

J Obstet Gynaecol Res. 2024 Aug;50(8):1362-1367. doi: 10.1111/jog.15970. Epub 2024 Jun 12.

Abstract

Background and aim: Pelvic inflammatory disease (PID) is usually managed by conservative treatment, but in selected cases, especially in the presence of a tubo-ovarian abscess (TOA), surgical management is a recognized treatment option. We compared the trends in managing PID and short-term outcomes before and during the SARS-CoV-2 pandemic.

Methods: This is a retrospective study performed in three Italian gynecological centers. We included patients admitted to hospital with a diagnosis of PID. Demographic characteristics, management, time to diagnosis, and time to treatment were compared before versus during the SARS-CoV-2 pandemic.

Results: One hundred nineteen PID patients were screened, eighty-one before the SARS-CoV-2 pandemic, and thirty-eight after the onset. At admission, leukocytosis (median 19.73 vs. 13.99 WBC/mm3, p-value = 0.02) was significantly higher in patients who underwent surgery after the onset of the pandemic. TOA incidence was higher in patients who underwent surgery during the SARS-CoV-2 pandemic, but the difference did not reach statistically significance (p = 0.06). The proportion of patients treated with surgery dropped to 26.3% after the onset from 46% of patients before the onset of pandemic (p = 0.03). Furthermore, a higher percentage of emergency surgical procedures on day 0 of hospital admission were performed after the onset of the pandemic (50% vs. 13.1%, p = 0.01).

Conclusions: In this retrospective cohort study, we found that the SARS-CoV-2 pandemic influenced the clinical presentation and management of PID in favor of conservative treatment. Patients who underwent surgery during the SARS-CoV-2 pandemic had higher inflammatory markers.

Keywords: COVID‐19; PID; SARS‐CoV‐2; management; pelvic inflammatory disease.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • COVID-19* / epidemiology
  • COVID-19* / therapy
  • Female
  • Humans
  • Italy / epidemiology
  • Middle Aged
  • Pelvic Inflammatory Disease* / epidemiology
  • Pelvic Inflammatory Disease* / surgery
  • Pelvic Inflammatory Disease* / therapy
  • Retrospective Studies
  • SARS-CoV-2